Subsidiary of Shanghai Shyndec Pharmaceutical, Guoyao Zhijun, intends to acquire the marketing authorization for the hydrochloride ethyphal impa-susan tablets (50mg).

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its controlling subsidiary, CSPC Shijun (Shenzhen) Pharmaceutical Co., Ltd. (hereinafter referred to as CSPC Shijun), has signed a "Drug Market Approval Transfer Agreement" with Shanghai Boyue Biotechnology Co., Ltd. (hereinafter referred to as Shanghai Boyue). Shanghai Boyue will transfer the market approval and related rights of its developed 50mg ethopropazine hydrochloride tablets to CSPC Shijun for a total transfer fee of RMB 10.5 million. Ethopropazine hydrochloride tablets are central muscle relaxants with clinical indications in two main areas: improving muscle tension in cervical shoulder arm syndrome, frozen shoulder, and lumbar pain; and treating spasm-induced paralysis, corresponding to high clinical disease rates. The product is recommended in multiple clinical diagnosis and treatment guidelines as the preferred treatment for acute muscle spasm, with proven clinical efficacy and good safety. The acquisition of the market approval for ethopropazine hydrochloride tablets (50mg) by CSPC Shijun aligns with the company's strategic development plan, enriching the company's skeletal muscle system drug product line and enhancing CSPC Shijun's market competitiveness. This transaction will not have a significant impact on the company's current operating performance.